Jaime A. Restrepo
Medellin, ANT, Colombia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
Journal: Papillomavirus research (Amsterdam, Netherlands)
Published: February 19, 2020
Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
Journal: Papillomavirus research (Amsterdam, Netherlands)
Published: September 20, 2017
4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years.
Journal: Pediatrics
Published: September 01, 2017
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.
Journal: Papillomavirus research (Amsterdam, Netherlands)
Published: September 23, 2016
Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines.
Journal: Pediatrics
Published: June 11, 2015
Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Journal: Human vaccines & immunotherapeutics
Published: April 28, 2015
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
Journal: The New England journal of medicine
Published: February 19, 2015
Long-term study of a quadrivalent human papillomavirus vaccine.
Journal: Pediatrics
Published: August 20, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026